Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers at the University of Illinois Urbana ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers at the University of Illinois ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers at the University of Illinois Urbana ...

TAGCyx Biotechnologies uses its proprietary Xenoligo technology platform to generate novel DNA aptamers containing an artificial nucleotide that have high affinity and selectivity for target proteins.

York-based biotech firm Aptamer Group has signed a “milestone” deal with the University of Glasgow for the use of its ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers at the University of Illinois Urbana ...

An aptamer (also known as a synthetic antibody) is a stable DNA, RNA, or peptide ligand that binds with high affinity and specificity to targets such as small molecules, peptides, proteins, biomarkers ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers report. The aptamers -- short single ...

A graphic showing, top to bottom, how DNA aptamers target two specific markers on a leukemia stem cell’s surface, enter the cell and deliver anticancer drugs, resulting in death of the cancer cell.